August 2020 | C. Lau | Physics of Plasmas | Paper
A quasi-neutral blended drift-Lorentz particle model of the field-reversed configuration (FRC) has been developed and implemented in the particle-in-cell code named ANC.
Prior to Coronavirus, human impact on the environment was largely studied in models and projections, making the cause and effect seem abstract to some. Now, we have all been partaking in an unprecedented living laboratory experiment, where the drastic reduction of planes, cars, and factory activity has led to results that are starkly visible in our everyday lives.
The Samberg Family Office has been a lead investor in TAE Technologies since our launch in 1998, and Art played an instrumental role in our company’s trajectory ever since. As an early champion, to member of the Board of Directors, and ultimately Chairman, Art has been there for us every step of the way in his longterm commitment to TAE. It is thanks to his unwavering support, audacious vision, and generous spirit that we are now on the cusp of the transformational clean energy solution he was so determined to help bring to the world. On behalf of the entire TAE team, we thank Art for his longtime support; and we wish peace and comfort to Art’s wife Becky and the entire Samberg family. May his memory be a blessing and an inspiration to us all. [L-R: Art Samberg, Heather Samberg, Jeff Samberg, Debbie Samberg]
The modern quest for Promethean fire is underway in an anonymous office park in Foothill Ranch, California, an hour southeast of Los Angeles. In the park, along a meandering drive, you will find a huge, modern warehouse building with “TAE Technologies” emblazoned on the door. Inside, you will find a 100-foot-long, $200 million fusion-energy experiment named Norman. And in a second-floor office, upstairs from that looming machine, you will find the would-be Prometheus himself: Michl Binderbauer, TAE’s boyish-looking and relentlessly upbeat co-founder and CEO.
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company’s initial funding in 2018.